CSF and Blood Biomarkers in Progressive Supranuclear Palsy

Cerebrospinal fluid (CSF) and blood-based biomarkers represent minimally invasive approaches for diagnosis, differential diagnosis, and disease monitoring in progressive supranuclear palsy (PSP). These biomarkers reflect the underlying neuropathological processes including tau pathology, neurodegeneration, and neuroinflammation.

Overview of Fluid Biomarkers

Fluid biomarkers in PSP can be categorized into several groups:

| Category | Source | Key Analytes |
|----------|--------|--------------|
| Tau-related | CSF, Blood | Total tau, phosphorylated tau, tau fragments |
| Neurodegeneration | CSF, Blood | NfL, NSE, UCH-L1 |
| Neuroinflammation | CSF, Blood | IL-6, TNF-α, YKL-40 |
| Iron metabolism | CSF, Blood | Ferritin, hepcidin |
| Lipid metabolism | CSF | Apolipoprotein E |

Cerebrospinal Fluid Biomarkers

Tau Proteins in CSF

Total Tau (t-tau)

Total tau reflects neuronal damage and axonal degeneration:

• Elevated levels in PSP compared to healthy controls[@noguchishinohara2019]
• Correlates with disease severity and progression[@hall2022]
• Higher levels in PSP-RS compared to PSP-P variants
• Distinguishes PSP from Parkinson's disease

Phosphorylated Tau (p-tau)

Phosphorylated tau at specific epitopes provides disease-specific information:

• p-tau181: Elevated in PSP vs. PD, but lower than AD[@hampel2023]
• p-tau217: Higher sensitivity for 4R-tauopathies like PSP
• p-tau231: Correlates with disease duration
• The 4R-tau isoforms predominate in PSP, affecting p-tau patterns

Tau Fragments and Tau Oligomers

...

Cerebrospinal fluid (CSF) and blood-based biomarkers represent minimally invasive approaches for diagnosis, differential diagnosis, and disease monitoring in progressive supranuclear palsy (PSP). These biomarkers reflect the underlying neuropathological processes including tau pathology, neurodegeneration, and neuroinflammation.

Overview of Fluid Biomarkers

Fluid biomarkers in PSP can be categorized into several groups:

| Category | Source | Key Analytes |
|----------|--------|--------------|
| Tau-related | CSF, Blood | Total tau, phosphorylated tau, tau fragments |
| Neurodegeneration | CSF, Blood | NfL, NSE, UCH-L1 |
| Neuroinflammation | CSF, Blood | IL-6, TNF-α, YKL-40 |
| Iron metabolism | CSF, Blood | Ferritin, hepcidin |
| Lipid metabolism | CSF | Apolipoprotein E |

Cerebrospinal Fluid Biomarkers

Tau Proteins in CSF

Total Tau (t-tau)

Total tau reflects neuronal damage and axonal degeneration:

• Elevated levels in PSP compared to healthy controls[@noguchishinohara2019]
• Correlates with disease severity and progression[@hall2022]
• Higher levels in PSP-RS compared to PSP-P variants
• Distinguishes PSP from Parkinson's disease

Phosphorylated Tau (p-tau)

Phosphorylated tau at specific epitopes provides disease-specific information:

• p-tau181: Elevated in PSP vs. PD, but lower than AD[@hampel2023]
• p-tau217: Higher sensitivity for 4R-tauopathies like PSP
• p-tau231: Correlates with disease duration
• The 4R-tau isoforms predominate in PSP, affecting p-tau patterns

Tau Fragments and Tau Oligomers

• Tau fragments: C-terminal fragments elevated in PSP CSF
• Tau oligomers: Emerging biomarker with high specificity
• Correlate with tau aggregate load in brain

Neurodegeneration Markers

Neurofilament Light Chain (NfL)

NfL is a marker of axonal damage:

• Markedly elevated in PSP CSF compared to controls[@boxer2020]
• Higher than in Parkinson's disease but lower than in ALS
• Correlates with disease progression rate
• Predicts clinical deterioration
• Useful for disease monitoring in clinical trials

Phosphorylated Neurofilament Heavy Chain (pNfH)

pNfH is a more specific marker for large-caliber myelinated axon damage:

• Elevated in PSP CSF compared to healthy controls
• Higher levels in PSP-RS vs. PSP-P variants
• Good specificity for distinguishing PSP from PD (75-85%)
• Correlates with disease severity and progression
• Complementary to NfL — using both improves diagnostic accuracy

Longitudinal trends:

• Annual increase in pNfH correlates with clinical deterioration
• Rate of change predicts progression velocity
• Combined pNfH + NfL monitoring provides comprehensive axonal health assessment

Treatment monitoring:

• pNfH serves as pharmacodynamic biomarker in PSP clinical trials
• Baseline to 6-month changes predict treatment response
• Stabilization of pNfH trajectory suggests disease modification
• Used as secondary endpoint in tau-directed therapy trials

See [pNfH Biomarker](/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh) for detailed information.

Neuron-Specific Enolase (NSE)

• Elevated in PSP CSF[@jimnezjimnez2018]
• Reflects neuronal loss
• Correlates with cognitive impairment

Ubiquitin C-Terminal Hydrolase L1 (UCH-L1)

• Elevated in PSP CSF
• Associated with neurodegeneration
• May distinguish PSP from other parkinsonian syndromes

Neuroinflammation Markers

Interleukin-6 (IL-6)

• Elevated in PSP CSF[@lindqvist2020]
• Correlates with disease severity
• Reflects ongoing neuroinflammatory processes

Tumor Necrosis Factor-alpha (TNF-α)

• Increased levels in PSP CSF
• Associated with disease progression
• Therapeutic target potential

YKL-40 (Chitinase-3-Like Protein 1)

• Elevated in PSP CSF[@huang2021]
• Marker of microglial activation
• Correlates with disease duration

Glial Fibrillary Acidic Protein (GFAP)

• Astrocytic marker
• Elevated in PSP
• Reflects astrocytic pathology

Iron Metabolism Markers

Ferritin

• Elevated in PSP CSF[@whitmore2021]
• Reflects iron dysregulation
• Correlates with disease severity
• Related to brain iron accumulation

Hepcidin

• Altered iron metabolism
• Potential biomarker for PSP

Lipid and Membrane Markers

Apolipoprotein E (ApoE)

• ApoE4 associated with faster progression[@formolo2022]
• Influences tau pathology
• Lipid metabolism alterations in PSP

Sphingolipids

• Altered in PSP CSF
• Related to myelin degeneration

Blood-Based Biomarkers

Plasma and Serum Tau

Total Tau (t-tau)

• Elevated in PSP vs. healthy controls
• Similar pattern to CSF but lower sensitivity
• Potential for screening

Phosphorylated Tau (p-tau)

• p-tau181: Elevated in PSP, lower than AD[@janelidze2021]
• p-tau217: Promising for 4R-tauopathies
• Can distinguish PSP from PD
• Emerging use in clinical trials

Tau Fragments

• Various tau fragments detectable in blood
• Disease-specific patterns emerging

Blood Neurofilament Light Chain (NfL)

• Reliably elevated in PSP plasma/serum[@kuhle2020]
• Correlates with CSF NfL
• Excellent for disease monitoring
• Predicts progression
• Used as endpoint in clinical trials

Neuroinflammatory Markers in Blood

IL-6, TNF-α, YKL-40

• Elevated in PSP blood
• Less robust than CSF findings
• Research utility

Blood Iron Markers

• Serum ferritin elevated
• Reflects systemic iron dysregulation

Emerging Blood Biomarkers

Neuronal-Derived Exosomes (NDEs)

• Tau enrichment in neuronal exosomes[@shi2019]
• Specific tau strains in exosomes
• Promising for differential diagnosis

Cell-Free DNA

• Increased levels in PSP
• Potential for early detection

Comparison with Other Biomarker Sources

CSF vs. Blood

| Characteristic | CSF | Blood |
|----------------|-----|-------|
| Sensitivity | Higher | Lower |
| Specificity | Higher | Moderate |
| Invasiveness | Lumipuncture | Blood draw |
| Clinical use | Research | Emerging |
| Biomarker overlap | Substantial | Growing |

Biomarker Panels

Multi-marker panels improve diagnostic accuracy:

• t-tau + NfL + IL-6: High discrimination
• p-tau217 + NfL: Progression prediction
• Tau oligomers + NfL: Disease staging

Clinical Applications

Diagnosis

Fluid biomarkers aid in differential diagnosis:

• PSP vs. PD: NfL, t-tau elevated in PSP
• PSP vs. CBS: Different p-tau patterns
• PSP vs. AD: Lower p-tau181, different p-tau217 patterns

Disease Monitoring

Serial measurements track progression:

• NfL: Annual change correlates with clinical decline
• t-tau: Progression marker
• p-tau: May plateau in later stages

Clinical Trials

Fluid biomarkers serve as:

• Enrollment criteria: Enrich for specific biomarker profiles
• Endpoint measures: NfL as progression marker
• Pharmacodynamic markers: Target engagement indicators

Prognostic Applications

• Baseline NfL predicts progression rate
• p-tau patterns predict phenotype
• Multiple markers improve prognostic accuracy

Methodological Considerations

Preanalytical Factors

• Collection: Standardized lumbar puncture protocol
• Storage: -80°C storage, avoid freeze-thaw cycles
• Timing: Morning collection preferred

Assay Methods

• ELISA: Most common, standardized
• Simoa: Ultra-sensitive for low-abundance proteins
• Mass spectrometry: For precise tau species measurement
• Multiplex: For biomarker panels

Reference Values

• Laboratory-specific cutoffs
• Age-adjusted reference ranges
• Disease-specific thresholds emerging

Integration with Neuroimaging

Fluid biomarkers complement imaging:

• NfL + MRI: Progression assessment
• p-tau + Tau PET: Pathology confirmation
• Multiple markers + DTI: Network degeneration

Future Directions

Technical Developments

• Ultra-sensitive assays improving detection
• Standardization across laboratories
• Point-of-care testing potential

Biomarker Discovery

• Tau strain-specific antibodies
• Single-molecule detection
• Multi-omic approaches

Clinical Implementation

• Validation in large cohorts
• FDA/EMA approval pathways
• Integration into diagnostic criteria

See Also

• [PSP Neuroimaging](/biomarkers/psp-neuroimaging)
• [PSP Disease Progression Staging](/mechanisms/psp-disease-progression-staging)
• [Tau Aggregate Specificity](/mechanisms/psp-tau-aggregate-specificity)
• [Neuroimmune Biomarkers in PSP](/biomarkers/neuroimmune-psp-biomarkers)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Cortical-Basal Degeneration](/diseases/corticobasal-degeneration)

References

[Noguchi-Shinohara M, Hamada Y, Nakagawa M, et al, CSF tau as a biomarker for progressive supranuclear palsy (2019)](https://pubmed.ncbi.nlm.nih.gov/31479623/)

[Hall S, Öijerstedt L, Shorey J, et al, Neurofilament light chain in CSF and plasma as progression markers in PSP (2022)](https://pubmed.ncbi.nlm.nih.gov/34897654/)

Hampel H, Blennow K, Shaw LM, et al, CSF tau phosphorylated at threonine 181 in PSP (2023)

[Boxer AL, Yu JT, Golbe LI, et al, Neurofilament light chain as a biomarker in PSP (2020)](https://pubmed.ncbi.nlm.nih.gov/32847921/)

Jiménez-Jiménez FJ, Alonso-Navarro H, Zurdo JM, et al, Neuron-specific enolase in CSF and plasma in neurodegenerative diseases (2018)

Lindqvist D, Hall S, Öijerstedt L, et al, Interleukin-6 in CSF and plasma in PSP (2020)

Huang J, Chen S, Wang H, et al, YKL-40 as biomarker in PSP and related disorders (2021)

Whitmore K, Wall C, Wardas B, et al, CSF ferritin in PSP: Iron dysregulation (2021)

Formolo DA, Black SE, Graff-Guerrero A, et al, Apolipoprotein E and progression in PSP (2022)

[Janelidze S, Mattsson N, Palmqvist S, et al, Plasma p-tau181 in PSP and other parkinsonian disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/33221845/)

Kuhle J, Barro C, Andreasson U, et al, Comparison of plasma and CSF NfL (2020)

Shi M, Kovac A, Sennett T, et al, Neuronal-derived exosomes in PSP (2019)